Zobrazeno 1 - 10 of 96 pro vyhledávání: '"IL-23p19"'
1
Akademický článek
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study
Autor: Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Olivia Choi, Yevgeniy Krol, Alice B. Gottlieb
Publikováno v: BMC Rheumatology, Vol 8, Iss 1, Pp 1-12 (2024)
Abstract Background Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic for patients with psoriatic arthritis (PsA). Given that many patients with PsA are TNFi inadequate responders (TNF-IR; either inadequate efficacy
Externí odkaz: https://doaj.org/article/8af8899c7fd64bf9a16ff7465d160dd3
Zobrazit plný text záznamu
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Successful treatment with cyclosporine and guselkumab for pityriasis rubra pilaris
Autor: Mai Nishimura, Makoto Kondo, Koji Habe, Akinobu Hayashi, Keiichi Yamanaka
Publikováno v: Clinical Case Reports, Vol 10, Iss 10, Pp n/a-n/a (2022)
Abstract A man with pityriasis rubra pilaris (PRP) showed no improvement in skin symptoms despite treatment with several drugs. The patient was diagnosed as having type 1 PRP. Combination therapy with cyclosporine and guselkumab improved his skin con
Externí odkaz: https://doaj.org/article/31486632d3734a3c9d07b679182c5194
Zobrazit plný text záznamu
5
Akademický článek
Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
Autor: Näslund-Koch C, Zachariae C, Skov L
Publikováno v: Therapeutics and Clinical Risk Management, Vol Volume 16, Pp 903-916 (2020)
Charlotte Näslund-Koch,1 Claus Zachariae,1,2 Lone Skov1,2 1Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen, Denmark; 2Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkCorrespondence
Externí odkaz: https://doaj.org/article/50580742ac354a1680217e87fab4c27b
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
8
Akademický článek
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
Autor: Beck KM, Sanchez IM, Yang EJ, Liao W
Publikováno v: Psoriasis: Targets and Therapy, Vol Volume 8, Pp 49-58 (2018)
Kristen M Beck, Isabelle M Sanchez, Eric J Yang, Wilson Liao Department of Dermatology, University of California San Francisco, San Francisco, CA, USA Abstract: Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in
Externí odkaz: https://doaj.org/article/cbdbae5932784b5585b125fc06cef0a8
Zobrazit plný text záznamu
9
Akademický článek
Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways
Autor: Georgina Espígol-Frigolé, Ester Planas-Rigol, Ester Lozano, Marc Corbera-Bellalta, Nekane Terrades-García, Sergio Prieto-González, Ana García-Martínez, Jose Hernández-Rodríguez, Josep M. Grau, Maria C. Cid
Publikováno v: Frontiers in Immunology, Vol 9 (2018)
BackgroundGiant-cell arteritis (GCA) is considered a T helper (Th)1- and Th17-mediated disease. Interleukin (IL)-12 is a heterodimeric cytokine (p35/p40) involved in Th1 differentiation. When combining with p19 subunit, p40 compose IL-23, a powerful
Externí odkaz: https://doaj.org/article/56f4a4a329ef4888a28f3b45da402ec8
Zobrazit plný text záznamu
10
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Autor: Dafna D. Gladman, Philip J. Mease, Paul Bird, Enrique R. Soriano, Soumya D. Chakravarty, May Shawi, Stephen Xu, Sean T. Quinn, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S. Helliwell, Arthur Kavanaugh, Atul Deodhar, Mikkel Østergaard, Xenofon Baraliakos
Publikováno v: Gladman, D D, Mease, P J, Bird, P, Soriano, E R, Chakravarty, S D, Shawi, M, Xu, S, Quinn, S T, Gong, C, Leibowitz, E, Poddubnyy, D, Tam, L S, Helliwell, P S, Kavanaugh, A, Deodhar, A, Østergaard, M & Baraliakos, X 2022, ' Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis : study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial ', Trials, vol. 23, 743 . https://doi.org/10.1186/s13063-022-06589-y
Background Axial involvement constitutes a specific domain of psoriatic arthritis (PsA). Interleukin (IL)-23 inhibitors have demonstrated improvement in axial PsA (axPsA) symptoms, but have not shown efficacy in treating ankylosing spondylitis (AS),
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba88bda62e553ef9488f13aed1f5ca03
https://doi.org/10.1186/s13063-022-06589-y
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje